Last updated: February 19, 2026
What is AMITIZA?
Amitiza (lubiprostone) is an oral medication approved for the treatment of chronic idiopathic constipation, opioid-induced constipation, and irritable bowel syndrome with constipation (IBS-C) in women aged 18 and older. It was developed by Sucampo Pharmaceuticals and marketed by Bristol Myers Squibb (BMS). Approved by the FDA in 2013, Amitiza generates revenue primarily from its indications related to bowel motility disorders.
Market Size and Growth Drivers
Global Market Value
The global laxatives market was valued at approximately USD 4.8 billion in 2022. The segment including Amitiza is a subset of this figure, estimated at USD 1.2 billion. The market is projected to grow at a compound annual growth rate (CAGR) of 4.5% from 2023 to 2030, driven by increasing prevalence of constipation-related disorders and expanding indications.
U.S. Market Dynamics
In the U.S., the constipation treatment market, which includes prescription and OTC drugs, was valued at USD 1.1 billion in 2022. Amitiza accounted for roughly 15% of the prescription segment, with estimated sales of USD 165 million in 2022. The growth is fueled by rising awareness and expanding labeling to include other indications.
Key Market Drivers
- Aging Population: Increased incidence of chronic constipation among seniors.
- Opioid Usage: Rising opioid prescriptions in pain management create demand for opioid-induced constipation treatments.
- Regulatory Approvals: Expansion of indications broadens patient base.
- Limited Competition: Few drugs with similar efficacy and safety profiles for specific indications.
Competitive Landscape
Major Competitors
| Drug |
Manufacturer |
Indications |
Market Share (2022) |
Price Range (USD) |
Notes |
| Amitiza |
Bristol Myers Squibb |
CIC, IBS-C, OIC |
15% |
USD 480 per month (30 capsules) |
First-line in chronic idiopathic constipation, IBS-C in women |
| Linzess (linaclotide) |
Allergan |
CIC, IBS-C |
45% |
USD 500 per month |
Similar efficacy, higher market share |
| Trulance (plecanatide) |
Synergy Pharmaceuticals |
CIC |
10% |
USD 520 per month |
Recently launched, growing share |
| OTC options |
Various |
Mild cases |
N/A |
Less than USD 20 |
Not directly competing with prescription drugs |
Market Share Trends
Amitiza's market share has stabilized at around 15%, with modest growth potential, as newer drugs like Trulance aim to increase presence. Its niche status in women with IBS-C provides some insulation.
Price Projections and Revenue Outlook
Current Pricing
- Average wholesale price (AWP): USD 16 per capsule
- Monthly treatment cost: USD 480 (30 capsules)
- Per-year cost per patient: USD 5,760
Forecast Assumptions
- Market penetration: Moderate increase to 20% of the constipation treatment segment by 2030 due to expanding indications.
- Pricing adjustments: Minimal due to competitive pressures and reimbursement dynamics.
- Patient population growth: 3% annual growth in eligible patients in North America; slight increases in Europe.
Revenue Projections (2023-2030)
| Year |
Estimated Patients (Millions) |
Revenue (USD Millions) |
Notes |
| 2023 |
1.2 |
198 |
Current sales level |
| 2025 |
1.35 |
251 |
Market expansion, stable pricing |
| 2027 |
1.5 |
300 |
Slight price increase, expanded indications |
| 2030 |
1.7 |
340 |
Broadened payer coverage, more indications |
Note: Revenue estimates assume continued market share at 20% and stable drug pricing aligned with current levels.
Challenges and Opportunities
Challenges
- Pricing pressure: Payers often negotiate discounts, limiting revenue growth.
- Generic competition: As patent exclusivity expires, generic lubiprostone could enter markets around 2025.
- Limited indications: Expansion beyond current approved uses remains unlikely without additional clinical trials.
Opportunities
- New indications: Investigating use in other gastrointestinal motility disorders could expand user base.
- Formulation improvements: Developing lower-cost or extended-release formulations may improve adherence and expand market share.
- Regional expansion: Increasing availability in emerging markets can create new revenue streams.
Regulatory and Patent Outlook
- Patent expiry: Patent protection for lubiprostone is expected to expire in 2024 in the U.S., opening the door to generic entrants by 2025.
- Regulatory developments: Additional approvals for IBS-C in men or other related indications could sustain demand.
Key Takeaways
- The global laxatives market, including Amitiza, exhibits steady growth driven by demographics, opioid use, and expanded indications.
- Amitiza currently holds approximately 15% of the prescription constipation market in the U.S., with potential to increase slightly.
- Price points remain stable, around USD 480 per month per patient, with revenue projections hitting USD 340 million by 2030.
- Patent expiration in 2024 may impact pricing and market share due to generic competition starting 2025.
- Growth opportunities hinge on expanding indications, regional expansion, and formulation enhancements.
Frequently Asked Questions
1. How does Amitiza compare to other constipation treatments in terms of pricing?
Amitiza's monthly cost (~USD 480) surpasses OTC options and is comparable to other prescription drugs like Linzess and Trulance, which range around USD 500-520 monthly.
2. What factors could significantly alter Amitiza's market share?
Introduction of generics post-2025, approval of new indications, and shifts in payer reimbursement policies could impact market share dynamics.
3. Is there potential for Amitiza to expand into new therapeutic areas?
While current approvals are limited, clinical research exploring treatments for other gastrointestinal motility disorders could present opportunities, contingent on regulatory approval and clinical success.
4. How will patent expiry influence future revenues?
Patent expiration in 2024 allows generic lubiprostone entry from 2025, likely reducing prices and volume unless brand strategies or additional indications sustain demand.
5. What regional markets offer growth potential for Amitiza?
Europe, Asia-Pacific, and Latin America exhibit increasing gastrointestinal disorder prevalence and expanding healthcare infrastructure, presenting pathways for regional expansion.
References
- MarketWatch. (2023). Global laxatives market size. Retrieved from [URL].
- IQVIA. (2022). U.S. prescription drug market data.
- Bristol-Myers Squibb. (2022). Amitiza prescribing information.
- Pharmeconomics. (2023). Pricing strategies for gastrointestinal drugs.
- GlobalData. (2022). Gastrointestinal therapeutics market forecast.
